CAMBRIDGE, England–(BUSINESS WIRE)–#EDXMedical–A new, highly accurate testing service that improves the early-stage detection of bowel cancer with strong clinicalCAMBRIDGE, England–(BUSINESS WIRE)–#EDXMedical–A new, highly accurate testing service that improves the early-stage detection of bowel cancer with strong clinical

EDX Medical’s New Advanced Bowel Cancer Testing Service to Launch in UK to Improve Early Detection

CAMBRIDGE, England–(BUSINESS WIRE)–#EDXMedical–A new, highly accurate testing service that improves the early-stage detection of bowel cancer with strong clinical validity will be available in the UK within the next few weeks.

The service increases the accuracy and sensitivity of testing and includes assessment of hereditary genetic risk for the patient. It is the most advanced and accurate colorectal testing solution ever to be offered in the UK, with sensitivities in excess of 95% across stages 1 to 4 bowel cancer and approximately 60% sensitivities for very early pre-cancerous adenomas.

The BC95 service, which is being launched in the UK by Cambridge-based digital diagnostic company, EDX Medical, comprises a customisable suite of diagnostic tests, tailored to individual patient needs. The testing service uses faecal and blood samples to examine a range of important biomarkers including hereditary genetic status. The service also includes pre-test counselling for hereditary risk assessment and all data from the various diagnostic procedures are returned to the patient’s designated healthcare provider or doctor for clinical follow-up.

Bowel, or colorectal, cancer is the second most common cause of cancer-related deaths worldwide. In the UK alone, there are 44,000 new cases each year. Someone contracts bowel cancer every 10 minutes and every 30 minutes someone dies from the disease. 75% of all newly diagnosed cases are missed by current screening methods.

Improved early detection and characterisation, including knowledge of hereditary genetic risks as well as the presence of adenomas is considered to be the most impactful area for cost-effectively improving patient outcomes.

Professor Sir Chris Evans, founder of EDX Medical, commented: “We are delighted to be providing a service in the UK that will take the testing for bowel cancer – Britain’s second biggest cancer killer – to a new level in terms of accuracy and reliability.

“The various elements of our service provide a very comprehensive testing package that has been thoroughly validated in the clinic and will not only improve vital early detection but also highlight hereditary risk.”

Dr Mike Hudson, chief executive officer, EDX Medical, commented: “There is growing demand for highly accurate testing solutions for the early detection of bowel and colon cancer in the UK, where late detection of the disease remains a significant cause of premature death. Our new service provides diagnostic tools which enable an assessment of hereditary risk and reliable, early detection when treatment options and outcomes are favourable”

EDX Medical has developed the unique testing service following an agreement with Genomictree of South Korea, to include the first in the UK, epigenetic, colorectal cancer (CRC) biomarker test; EarlyTect® C that measures aberrant SDC2 (Syndecan 2 gene) promoter region methylation, a marker that is frequently observed in early-stage colorectal cancer tissues. It is the most sensitive and accurate epigenetic biomarker test for colorectal cancer currently available on the UK market.

In a cohort of 1124 asymptomatic patients with an overall disease incidence of 1.8%, the test has been shown to have an average sensitivity of 95% for detecting colorectal cancer across stages 1- 4, with exceptionally high sensitivity (89.1%) for detecting early-stage cancers (stage 0-2). The test even detects pre-cancerous advanced adenomatous polyps with a sensitivity of 58.1% making it a particularly useful tool for monitoring those known to have an increased risk of cancer due to hereditary genetics or lifestyle.

The testing service also incorporates currently available test methods such as qFIT, providing additional information allowing clinicians to accurately guide further diagnostic interventions such as colonoscopy or CT colonography.

For those individuals with a family history of CRC, testing can be used to guide lifestyle choices as well as guide the frequency with which the early detection elements of the service should be used. The hereditary genetic element of the BC95 service involves comprehensive pre-and post-test genetic counselling, including determining a family history of cancer, and support to access public and private resources in cases where a positive result is identified. The hereditary risk test and pre-test counselling is a once-only procedure for each individual.

In colorectal cancer, patient outcomes, principally five-year survival, are closely linked to the stage at which the disease is diagnosed: Patients diagnosed at stage 1 have a 90% five-year survival rate. For patients diagnosed at stage 2, the five-year survival figure is 85%. This figure drops dramatically if patients are diagnosed with later-stage disease. Figures for five-year survival at stage 4 are 10% or lower. This stark statistic emphasises the benefits of early detection and thus the importance of effective screening and detection technologies.

The EDX Medical BC95 bowel cancer service aims to be the most reliable, early detection test and comprises an assessment of:

  • An extensive panel of hereditary genetic risks (including Lynch syndrome)
  • Advanced early detection technology to identify epigenetic biomarkers in faecal DNA
  • The standard FIT assessment of faecal haemoglobin – enabling reference to legacy data.

Notes for Editors:

About EDX Medical Group plc

EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

EDX Medical conducts product development, validation and distribution and provides PCR and genomic sequencing services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).

Contacts

EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)

+44 (0)7812 345 301

Media House International
Ramsay Smith

+44 (0)7788 414856

ramsay@mediahouse.co.uk

Gary McQueen

+ 44 (0)7834 694609

gary@mediahouse.co.uk

Market Opportunity
EDEXA BLOCKCHAIN Logo
EDEXA BLOCKCHAIN Price(EDX)
$0.008
$0.008$0.008
+10.81%
USD
EDEXA BLOCKCHAIN (EDX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security

Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security

BitcoinWorld Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security Ever wondered why withdrawing your staked Ethereum (ETH) isn’t an instant process? It’s a question that often sparks debate within the crypto community. Ethereum founder Vitalik Buterin recently stepped forward to defend the network’s approximately 45-day ETH unstaking period, asserting its crucial role in safeguarding the network’s integrity. This lengthy waiting time, while sometimes seen as an inconvenience, is a deliberate design choice with profound implications for security. Why is the ETH Unstaking Period a Vital Security Measure? Vitalik Buterin’s defense comes amidst comparisons to other networks, like Solana, which boast significantly shorter unstaking times. He drew a compelling parallel to military operations, explaining that an army cannot function effectively if its soldiers can simply abandon their posts at a moment’s notice. Similarly, a blockchain network requires a stable and committed validator set to maintain its security. The current ETH unstaking period isn’t merely an arbitrary delay. It acts as a critical buffer, providing the network with sufficient time to detect and respond to potential malicious activities. If validators could instantly exit, it would open doors for sophisticated attacks, jeopardizing the entire system. Currently, Ethereum boasts over one million active validators, collectively staking approximately 35.6 million ETH, representing about 30% of the total supply. This massive commitment underpins the network’s robust security model, and the unstaking period helps preserve this stability. Network Security: Ethereum’s Paramount Concern A shorter ETH unstaking period might seem appealing for liquidity, but it introduces significant risks. Imagine a scenario where a large number of validators, potentially colluding, could quickly withdraw their stake after committing a malicious act. Without a substantial delay, the network would have limited time to penalize them or mitigate the damage. This “exit queue” mechanism is designed to prevent sudden validator exodus, which could lead to: Reduced decentralization: A rapid drop in active validators could concentrate power among fewer participants. Increased vulnerability to attacks: A smaller, less stable validator set is easier to compromise. Network instability: Frequent and unpredictable changes in validator numbers can lead to performance issues and consensus failures. Therefore, the extended period is not a bug; it’s a feature. It’s a calculated trade-off between immediate liquidity for stakers and the foundational security of the entire Ethereum ecosystem. Ethereum vs. Solana: Different Approaches to Unstaking When discussing the ETH unstaking period, many point to networks like Solana, which offers a much quicker two-day unstaking process. While this might seem like an advantage for stakers seeking rapid access to their funds, it reflects fundamental differences in network architecture and security philosophies. Solana’s design prioritizes speed and immediate liquidity, often relying on different consensus mechanisms and validator economics to manage security risks. Ethereum, on the other hand, with its proof-of-stake evolution from proof-of-work, has adopted a more cautious approach to ensure its transition and long-term stability are uncompromised. Each network makes design choices based on its unique goals and threat models. Ethereum’s substantial value and its role as a foundational layer for countless dApps necessitate an extremely robust security posture, making the current unstaking duration a deliberate and necessary component. What Does the ETH Unstaking Period Mean for Stakers? For individuals and institutions staking ETH, understanding the ETH unstaking period is crucial for managing expectations and investment strategies. It means that while staking offers attractive rewards, it also comes with a commitment to the network’s long-term health. Here are key considerations for stakers: Liquidity Planning: Stakers should view their staked ETH as a longer-term commitment, not immediately liquid capital. Risk Management: The delay inherently reduces the ability to react quickly to market volatility with staked assets. Network Contribution: By participating, stakers contribute directly to the security and decentralization of Ethereum, reinforcing its value proposition. While the current waiting period may not be “optimal” in every sense, as Buterin acknowledged, simply shortening it without addressing the underlying security implications would be a dangerous gamble for the network’s reliability. In conclusion, Vitalik Buterin’s defense of the lengthy ETH unstaking period underscores a fundamental principle: network security cannot be compromised for the sake of convenience. It is a vital mechanism that protects Ethereum’s integrity, ensuring its stability and trustworthiness as a leading blockchain platform. This deliberate design choice, while requiring patience from stakers, ultimately fortifies the entire ecosystem against potential threats, paving the way for a more secure and reliable decentralized future. Frequently Asked Questions (FAQs) Q1: What is the main reason for Ethereum’s long unstaking period? A1: The primary reason is network security. A lengthy ETH unstaking period prevents malicious actors from quickly withdrawing their stake after an attack, giving the network time to detect and penalize them, thus maintaining stability and integrity. Q2: How long is the current ETH unstaking period? A2: The current ETH unstaking period is approximately 45 days. This duration can fluctuate based on network conditions and the number of validators in the exit queue. Q3: How does Ethereum’s unstaking period compare to other blockchains? A3: Ethereum’s unstaking period is notably longer than some other networks, such as Solana, which has a two-day period. This difference reflects varying network architectures and security priorities. Q4: Does the unstaking period affect ETH stakers? A4: Yes, it means stakers need to plan their liquidity carefully, as their staked ETH is not immediately accessible. It encourages a longer-term commitment to the network, aligning staker interests with Ethereum’s stability. Q5: Could the ETH unstaking period be shortened in the future? A5: While Vitalik Buterin acknowledged the current period might not be “optimal,” any significant shortening would likely require extensive research and network upgrades to ensure security isn’t compromised. For now, the focus remains on maintaining robust network defenses. Found this article insightful? Share it with your friends and fellow crypto enthusiasts on social media to spread awareness about the critical role of the ETH unstaking period in Ethereum’s security! To learn more about the latest Ethereum trends, explore our article on key developments shaping Ethereum’s institutional adoption. This post Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security first appeared on BitcoinWorld.
Share
Coinstats2025/09/18 15:30
Shiba Inu Price Forecast: Why This New Trending Meme Coin Is Being Dubbed The New PEPE After Record Presale

Shiba Inu Price Forecast: Why This New Trending Meme Coin Is Being Dubbed The New PEPE After Record Presale

While Shiba Inu (SHIB) continues to build its ecosystem and PEPE holds onto its viral roots, a new contender, Layer […] The post Shiba Inu Price Forecast: Why This New Trending Meme Coin Is Being Dubbed The New PEPE After Record Presale appeared first on Coindoo.
Share
Coindoo2025/09/18 01:13
The U.S. Financial Accounting Standards Board plans to study in 2026 whether crypto assets such as stablecoins can be classified as cash equivalents.

The U.S. Financial Accounting Standards Board plans to study in 2026 whether crypto assets such as stablecoins can be classified as cash equivalents.

PANews reported on December 31 that the Financial Accounting Standards Board (FASB) plans to study in 2026 whether certain crypto assets can be classified as cash
Share
PANews2025/12/31 16:50